Clearside Biomedical Inc (CLSD) Noticias

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a...

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a...

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a...

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs...

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report